Loading...
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
OBJECTIVES: We report 2-year results from CheckMate 141 to establish the long-term efficacy and safety profile of nivolumab and outcomes by tumor PD-L1 expression in patients with recurrent or metastatic (R/M),platinum-refractory squamous cell carcinoma of the head and neck (SCCHN). METHODS: Patient...
Na minha lista:
| Udgivet i: | Oral Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6563923/ https://ncbi.nlm.nih.gov/pubmed/29884413 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2018.04.008 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|